Molecular and Genetic Aspects of Odontogenic Lesions

被引：13
作者：
Bilodeau E.A. [1 ]
Prasad J.L. [1 ]
Alawi F. [2 ]
Seethala R.R. [3 ]
机构：
[1] Department of Diagnostic Sciences, University of Pittsburgh School of Dental Medicine, Pittsburgh, 15261, PA
[2] Department of Pathology, University of Pennsylvania School of Dental Medicine, Philadelphia, PA
[3] Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA
来源：
Head and Neck Pathology | 2014年 / 8卷 / 4期
关键词：
BRAF; EWSR1; Molecular pathology; Mutation; Odontogenic tumors; PTCH; Translocation;
D O I：
10.1007/s12105-014-0588-7
中图分类号：
学科分类号：
摘要：
In this article we outline the molecular findings of select odontogenic tumors. In each section, we briefly review selected the clinicoradiographic, histologic, immunologic features, focusing on the molecular findings and their applications in practice. The understanding of molecular pathobiology at various other organ sites has developed quite rapidly in recent years, however much remains unknown about the genetic profile of odontogenic tumors. Improved understanding of mutations in odontogenic tumors may clarify classification schema and elucidate targets for novel therapies. Molecular testing will no doubt improve our understanding of odontogenic tumor pathogenesis and will likely be, someday, an important component of routine clinical practice and its role will only increase in the coming years. © 2014, Springer Science+Business Media New York.
引用
收藏
页码：400 / 410
页数：10
相关论文
共 74 条
[1]  
Barnes L., Eveson J., Reichart P., Sidransky D., Pathology and genetics of head and neck tumours, (2005)
[2]  
Takeda Y., Ameloblastic fibroma and related lesions: current pathologic concept, Oral Oncol, 35, 6, pp. 535-540, (1999)
[3]  
Muller S., Parker D.C., Kapadia S.B., Budnick S.D., Barnes E.L., Ameloblastic fibrosarcoma of the jaws. A clinicopathologic and DNA analysis of five cases and review of the literature with discussion of its relationship to ameloblastic fibroma, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 79, 4, pp. 469-477, (1995)
[4]  
Neville B.W., Allen C.M., Bouquot J.E., Odontogenic cysts and tumors. Oral and maxillofacial pathology. 3rd ed. St, Louis: Saunders Elsevier, 2009, pp. 678-740
[5]  
Galvao C.F., Gomes C.C., Diniz M.G., Vargas P.A., de Paula A.M., Mosqueda-Taylor A., Et al., Loss of heterozygosity (LOH) in tumour suppressor genes in benign and malignant mixed odontogenic tumours, J Oral Pathol Med, 41, 5, pp. 389-393, (2012)
[6]  
Williams M.D., Hanna E.Y., El-Naggar A.K., Anaplastic ameloblastic fibrosarcoma arising from recurrent ameloblastic fibroma: restricted molecular abnormalities of certain genes to the malignant transformation, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 104, 1, pp. 72-75, (2007)
[7]  
Brown N.A., Rolland D., McHugh J.B., Weigelin H.C., Zhao L., Lim M.S., Et al., Activating FGFR2-RAS-BRAF mutations in ameloblastoma, Clin Cancer Res, (2014)
[8]  
Sarkar A., Hochedlinger K., The sox family of transcription factors: versatile regulators of stem and progenitor cell fate, Cell Stem Cell, 12, 1, pp. 15-30, (2013)
[9]  
Evaluation of SOX2 as a potential marker for ameloblastic carcinoma, Oral Surg Oral Med Oral Pathol Oral Radiol., (2014)
[10]  
Heikinheimo K., Voutilainen R., Happonen R.P., Miettinen P.J., EGF receptor and its ligands, EGF and TGF-alpha, in developing and neoplastic human odontogenic tissues, Int J Dev Biol, 37, 3, pp. 387-396, (1993)
12345678